0000950170-24-104047.txt : 20240905 0000950170-24-104047.hdr.sgml : 20240905 20240905163509 ACCESSION NUMBER: 0000950170-24-104047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240829 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALLURION TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001964979 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41767 FILM NUMBER: 241281857 BUSINESS ADDRESS: STREET 1: 11 HURON DR STE 200 CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-647-4000 MAIL ADDRESS: STREET 1: 11 HURON DR STE 200 CITY: NATICK STATE: MA ZIP: 01760 FORMER COMPANY: FORMER CONFORMED NAME: ALLURION TECHNOLOGIES HOLDINGS, INC. DATE OF NAME CHANGE: 20230207 8-K 1 alur-20240829.htm 8-K 8-K
0001964979false0001964979alur:WarrantsToPurchase1420455SharesOfCommonStockEachAtAnExercisePriceOf810PerShareOfCommonStockMember2024-08-292024-08-290001964979alur:CommonStockParValue00001PerShareMember2024-08-292024-08-2900019649792024-08-292024-08-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2024

 

 

Allurion Technologies, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41767

92-2182207

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11 Huron Drive

 

Natick, Massachusetts

 

01760

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (508) 647-4000

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ALUR

 

The New York Stock Exchange

Warrants to purchase 1.420455 shares of common stock, each at an exercise price of $8.10 per share of common stock

 

ALUR WS

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 29, 2024, Allurion Technologies, Inc. (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) because the average market capitalization of the Company was less than $50.0 million over the consecutive 30 trading-day period ended August 29, 2024 and the Company’s last reported stockholders’ equity as of August 29, 2024 was less than $50.0 million. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE.

In accordance with applicable NYSE procedures, within 45 days from receipt of the Notice, the Company intends to submit a plan to the NYSE advising it of the definitive action(s) the Company has taken, is taking, or plans to take that would bring it into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice (the “Cure Period”). Upon receipt of such plan, the NYSE will evaluate the plan and determine whether the Company has made a reasonable demonstration of its ability to come into conformity with the relevant listing standards within the Cure Period. If the NYSE accepts the Company’s plan, the NYSE will review the Company on a quarterly basis to confirm compliance with the plan. If the Company’s plan is not accepted, the Company fails to comply with the plan or does not meet the Minimum Market Capitalization Standard at the end of the Cure Period, it will be subject to NYSE’s prompt initiation of suspension and delisting procedures.

The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during such cure period, subject to the Company’s compliance with other NYSE continued listing standards. The Company’s common stock will continue to trade on the NYSE under the symbol “ALUR” with the designation of “.BC” to indicate the status of the shares as “below criteria.” If the Company does not regain compliance with the Minimum Market Capitalization Standard, the Company’s common stock will be subject to suspension and delisting from the NYSE. If the Company’s common stock ultimately were to be delisted, it could negatively impact the Company by reducing the liquidity and market price of the Company’s common stock. Furthermore, the Notice is not anticipated to impact the ongoing business operations of the Company or its reporting requirements with the U.S. Securities and Exchange Commission.

The Company had previously received a notice on August 12, 2024 that the Company was not in compliance with NYSE’s minimum average closing price listing requirement in Section 802.01A of the NYSE Listed Company Manual.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the Company’s plans to notify the NYSE that it intends to cure the market capitalization deficiency and return to compliance with the applicable NYSE continued listing standards, its intention to remain listed on the NYSE, and its options to regain compliance with the NYSE’s continued listing standards. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of the Company’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of the Company to obtain and maintain regulatory approvals for and successfully commercialize its products and offerings, including the Allurion Balloon, (ii) the timing of, and results from, the Company’s clinical studies and trials, (iii) the evolution of the markets in which the Company competes, (iv) the ability of the Company to defend its intellectual property and satisfy regulatory requirements, (v) the impact of global economic conditions and geopolitical events on the Company’s business, (vi) the Company’s expectations regarding its market opportunities, (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates, (viii) the risk that the Notice and noncompliance with NYSE continued listing standards may impact the Company’s results of operations, business operations and reputation and the trading prices and volatility of the Company’s common stock, and (ix) the Company’s ability to continue to meet NYSE continued listing standards. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

Item 7.01 Regulation FD Disclosure.

As required by Section 802.01B, the Company issued a press release on September 5, 2024, announcing that it had received the notice of noncompliance with the NYSE’s continued listing standards. A copy of the press release is being furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

 

 

Exhibit

Description

99.1

Press Release of Allurion Technologies, Inc., dated September 5, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ALLURION TECHNOLOGIES, INC.

 

 

 

 

Date:

September 5, 2024

By:

/s/ Brendan Gibbons

 

 

Name:

Title:

Brendan Gibbons
Chief Legal Officer

 

 EX-99.1 2 alur-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Allurion Receives Continued Listing Standards Notice from NYSE

September 5, 2024

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average market capitalization of the Company was less than $50.0 million over the consecutive 30 trading-day period ended August 29, 2024 and the Company’s last reported stockholders’ equity as of August 29, 2024 was less than $50.0 million. The Notice does not result in the immediate delisting of the Company’s common stock from the NYSE.

In accordance with NYSE procedures, within 45 days from receipt of the Notice, the Company intends to submit a plan to the NYSE advising it of the definitive action(s) the company has taken, is taking, or plans to take that would bring it into conformity with the continued listing standards. If the NYSE accepts the Company’s plan, the Company’s common stock will continue to be listed and traded on the NYSE during the 18-month cure period, subject to the Company’s compliance with other NYSE continued listing standards and continued periodic review by the NYSE of the Company’s progress with respect to its plan.

The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during such cure period, subject to the Company’s compliance with other NYSE continued listing standards. Furthermore, the Notice is not anticipated to impact the ongoing business operations of the Company or its reporting requirements with the U.S. Securities and Exchange Commission.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, Procedureless™ intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

 

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the Company’s plans to notify the NYSE hat it intends to cure the market capitalization deficiency and return to compliance with the applicable NYSE continued listing standards, its intention to remain listed on the NYSE, and its options to regain compliance with the

 

 

NYSE’s continued listing standards. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of the Company’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of the Company to obtain and maintain regulatory approvals for and successfully commercialize its products and offerings, including the Allurion Balloon, (ii) the timing of, and results from, the Company’s clinical studies and trials, (iii) the evolution of the markets in which the Company competes, (iv) the ability of the Company to defend its intellectual property and satisfy regulatory requirements, (v) the impact of global economic conditions and geopolitical events on the Company’s business, (vi) the Company’s expectations regarding its market opportunities, (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates, (viii) the risk that the Notice and noncompliance with NYSE continued listing standards may impact the Company’s results of operations, business operations and reputation and the trading prices and volatility of the Company’s common stock, and (ix) the Company’s ability to continue to meet NYSE continued listing standards. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor Contact

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

 

 EX-101.SCH 3 alur-20240829.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Warrants to purchase1.420455 shares of common stock each at an exercise price of8.10 per share of common stock. Warrants To Purchase1.420455 Shares Of Common Stock Each At An Exercise Price Of8.10 Per Share Of Common Stock [Member] Class of Stock [Axis] Class of Stock [Domain] Common stock par value 0.0001 per share. Common Stock Par Value 0.0001 Per Share [Member] XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document And Entity Information
Aug. 29, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 29, 2024
Entity Registrant Name Allurion Technologies, Inc.
Entity Central Index Key 0001964979
Entity Emerging Growth Company true
Entity File Number 001-41767
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 92-2182207
Entity Address, Address Line One 11 Huron Drive
Entity Address, City or Town Natick
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01760
City Area Code (508)
Local Phone Number 647-4000
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Common Stock Par Value 0.0001 Per Share [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ALUR
Security Exchange Name NYSE
Warrants To Purchase1.420455 Shares Of Common Stock Each At An Exercise Price Of8.10 Per Share Of Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants to purchase 1.420455 shares of common stock, each at an exercise price of $8.10 per share of common stock
Trading Symbol ALUR WS
Security Exchange Name NYSE
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports alur-20240829.htm alur-20240829.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "alur-20240829.htm": { "nsprefix": "alur", "nsuri": "http://www.allurion.com/20240829", "dts": { "inline": { "local": [ "alur-20240829.htm" ] }, "schema": { "local": [ "alur-20240829.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 27 }, "report": { "R1": { "role": "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_61f0f58d-6365-4542-bf87-5184579f7109", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "alur-20240829.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_61f0f58d-6365-4542-bf87-5184579f7109", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "alur-20240829.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "alur_CommonStockParValue00001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.allurion.com/20240829", "localname": "CommonStockParValue00001PerShareMember", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Common stock par value 0.0001 per share.", "label": "Common Stock Par Value 0.0001 Per Share [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "alur_WarrantsToPurchase1420455SharesOfCommonStockEachAtAnExercisePriceOf810PerShareOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.allurion.com/20240829", "localname": "WarrantsToPurchase1420455SharesOfCommonStockEachAtAnExercisePriceOf810PerShareOfCommonStockMember", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase1.420455 shares of common stock each at an exercise price of8.10 per share of common stock.", "label": "Warrants To Purchase1.420455 Shares Of Common Stock Each At An Exercise Price Of8.10 Per Share Of Common Stock [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.allurion.com/20240829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-104047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-104047-xbrl.zip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end XML 14 alur-20240829_htm.xml IDEA: XBRL DOCUMENT 0001964979 alur:WarrantsToPurchase1420455SharesOfCommonStockEachAtAnExercisePriceOf810PerShareOfCommonStockMember 2024-08-29 2024-08-29 0001964979 alur:CommonStockParValue00001PerShareMember 2024-08-29 2024-08-29 0001964979 2024-08-29 2024-08-29 0001964979 false 8-K 2024-08-29 Allurion Technologies, Inc. DE 001-41767 92-2182207 11 Huron Drive Natick MA 01760 (508) 647-4000 Not Applicable false false false false Common stock, par value $0.0001 per share ALUR NYSE Warrants to purchase 1.420455 shares of common stock, each at an exercise price of $8.10 per share of common stock ALUR WS NYSE true false